Norman Wong presented a 15 minute oral presentation at EASD 2018 this morning (afternoon in Berlin) entitled "Apabetalone (RVX-208) an epigenetic modifier lowers risk of MACE in diabetes patients with CVD by affecting monocyte adhesion to endothelial cells." The presentation was not made available on the EASD website or promoted by Resverlogix other than a brief mention on their September fact sheet. You can read the abstract for the EASD presentation here.
As previously mentioned, this was at least the 4th presentation of this abstract in the past 5 months (Vascular Discovery 2018 in May, International Symposium on Atherosclerosis 2018 in June, American Diabetes Association 2018 in June, European Society for the Study of Diabetes 2018 today). Resverlogix hasn't made any of these posters/presentations available on their website and to my best recollection hasn't news released about them either. They've been very quiet about this FXR story. The fact that they are presenting it so frequently suggests that they view it as a significant finding, and presumbably good news since they aren't shy from presenting it. Perhaps it is too complex of a story for them to capture in a news release and we'll have to wait for this stuff to be published in a peer-review journal to get the big scoop.
Resverlogix also presented an oral presentation at ESC 2018 back in August entitled "Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta." This abstract/presentation was not made available either. I inquired about this with Sarah a while back and received a reply "This data is pending publication so the presentation cannot be posted to the website at this time due to embargo policy." This ESC presentation may or may not be related to the FXR story (it's hard to tell since ESC abstract was not made available). It could be that today's EASD presentation is also under embargo for similar reasons as the ESC abstract and that is why the EASD presentation isn't being made available (EASD virtual meeting allow presenters option of making their presentations available online).
Anyways, seems that at least 1 publication is in the works. Hopefully we see these publication(s) in press soon so we can read the more comprehensive big picture on these findings.
BearDownAZ
